Skip to main content

MoneyWorks4Me

A fair growth of 17.13% in the revenue at Rs. 1913.45 millions was reported in the September 2026 quarter as compared to Rs. 1633.64 millions during year-ago period.Profit for the quarter ended September 2026 increased merely by2.21% to Rs. 204.26  millions from Rs. 199.84 millions.Operating profit for the quarter ended September 2026 rose to 332.20 millions as compared to 326.60 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 1913.45 1633.64 17.13 3686.27 3174.31 16.13 6710.30 6232.30 7.67
Other Income 95.34 72.32 31.83 337.99 225.04 50.19 334.54 224.77 48.84
PBIDT 332.20 326.60 1.71 849.16 717.36 18.37 1311.37 1239.71 5.78
Interest 3.18 2.31 37.66 5.77 4.41 30.84 10.13 18.83 -46.20
PBDT 329.02 324.29 1.46 843.39 712.95 18.30 1301.24 1220.88 6.58
Depreciation 38.84 36.19 7.32 77.68 70.96 9.47 145.00 128.99 12.41
PBT 290.18 288.10 0.72 765.71 641.99 19.27 1156.24 1091.89 5.89
TAX 85.92 88.26 -2.65 199.11 165.40 20.38 277.31 268.42 3.31
Deferred Tax -8.48 -1.25 578.40 51.18 34.66 47.66 -0.31 15.15 -102.05
PAT 204.26 199.84 2.21 566.60 476.59 18.89 878.93 823.47 6.73
Equity 200.30 200.30 0.00 200.30 200.30 0.00 200.30 200.30 0.00
PBIDTM(%) 17.36 19.99 -13.16 23.04 22.60 1.93 19.54 19.89 -1.76
Peers
Company Name CMP
Sun Pharma. Inds. 1769.00
Dr. Reddys Labs. 1355.70
Cipla 1378.30
Lupin 2024.50
Zydus Lifesciences 1238.95
View more..